Mitochondrial Carbonic Anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models
Lemon, N. L.; Canepa, E.; Vazquez-Torres, R.; Parodi-Rullan, R.; Hirt, T.; Petersohn, L. M.; Rifat, T.; Abyaneh, M. H.; Ilies, M. A.; Fossati, S.
Show abstract
Alzheimers Disease (AD) is a devastating neurodegenerative disorder with no effective cure, characterized by the cerebral parenchymal and vascular accumulation of aggregated Amyloid-{beta} (A{beta}) and hyperphosphorylated tau. Cerebrovascular and mitochondria dysfunction are early causal events in the progression of AD. Previous studies support that inhibiting carbonic anhydrases (CA) may prevent mitochondrial and cerebrovascular dysfunction in AD models. Here, we selectively target the mitochondrial CA isoform CA-VB by pharmacological and genetic manipulation, in human cerebral microvascular endothelial cells (hCMEC) and we confirm the protective effects of the CA-V inhibitor in AD mice. CA-V inhibition and CA-VB KO prevent A{beta} induced mitochondria-mediated endothelial apoptosis, loss of barrier resistance, and hCMEC inflammatory activation. Strikingly, CA-V inhibition also mitigates caspase activation and endothelial cell activation in the brains of 3xTg AD mice, resulting in preserved memory function. Our results demonstrate that selective CA-V inhibition is an effective and promising strategy against AD-mediated cerebrovascular pathology, neuroinflammation and cognitive impairment.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AIM2 Inflammasome Mediates Hallmark Neuropathological Alterations and Cognitive Impairment in a Mouse Model of Vascular Dementia 95%
- Alzheimer's Disease Patient Brain Extracts Induce Multiple Pathologies in Vascularized Neuroimmune Organoids for Disease Modeling and Drug Discovery 95%
- Tau depletion in human neurons mitigates A beta-driven toxicity 95%
Similar papers in this journal
- Neuroprotection in early stages of Alzheimers Disease is promoted by Transthyretin angiogenic properties 96%
- A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease 96%
- New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer's disease 96%
Similar papers in this journal
- Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone 97%
- Queuine, a bacterial derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration 96%
- ACE1 Does Not Influence Cerebral Aβ Degradation or Amyloid Plaque Accumulation in 5XFAD Mice 96%
Similar papers in this journal
- Social and Contextual Memory Impairments Induced by Amyloid-β Oligomers are Rescued by Sigma-1 Receptor Activation 96%
- Drug repurposing of dopaminergic drugs to inhibit Ataxin-3 aggregation 94%
- Combining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer's disease 94%